Bioavailability is expressed as a percentage or fraction (commonly abbreviated F) relative to an intravenous reference dose, which is assigned 100% bioavailability because it bypasses all absorption barriers and enters the bloodstream directly. For all other routes , oral, sublingual, transdermal, inhaled, and so on , the figure is lower, sometimes substantially so.
Two primary processes determine how much of a substance actually reaches circulation: absorption (the movement of the compound across biological membranes from the site of administration) and first-pass metabolism (pre-systemic breakdown, most commonly in the gut wall and liver, that reduces the active fraction before it enters the general circulation). A compound with high intestinal absorption but extensive hepatic first-pass metabolism may still carry a low overall bioavailability.
In pharmacological research, bioavailability data inform dosing calculations, formulation design, and route-of-administration decisions. For plant-derived and cannabinoid compounds specifically, bioavailability is a particularly active area of study because lipophilic molecules such as cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) show wide inter-individual variability depending on food co-ingestion, particle size, and formulation matrix. Published estimates for oral CBD bioavailability in fasted adults, for example, range from roughly 6% to 19% in peer-reviewed literature, highlighting the limitations of comparing products or study results without accounting for formulation differences.
Bioavailability is distinct from potency (the amount of a substance required to produce a given biochemical effect) and from efficacy (the maximum response a substance can produce). A highly potent compound with poor bioavailability may require formulation strategies , lipid-based delivery systems, nanoemulsification, or alternative routes; to achieve measurable systemic exposure in research models.
Sources: